Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
6(50%)
Results Posted
200%(2 trials)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
1
8%
Ph phase_3
2
17%
Ph phase_2
6
50%
Ph phase_4
2
17%

Phase Distribution

0

Early Stage

6

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
6(54.5%)
Phase 3Large-scale testing
2(18.2%)
Phase 4Post-market surveillance
2(18.2%)
N/ANon-phased studies
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

6

trials recruiting

Total Trials

12

all time

Status Distribution
Active(8)
Completed(1)
Terminated(2)
Other(1)

Detailed Status

Recruiting5
Not yet recruiting2
unknown1
Withdrawn1
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
6
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 26 (54.5%)
Phase 32 (18.2%)
Phase 42 (18.2%)
N/A1 (9.1%)

Trials by Status

unknown18%
withdrawn18%
active_not_recruiting18%
completed18%
terminated18%
not_yet_recruiting217%
recruiting542%

Recent Activity

6 active trials
Showing 5 of 12
recruitingphase_4

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

NCT07704658
active_not_recruitingphase_2

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

NCT04589845
recruitingphase_2

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

NCT04302025
recruiting

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

NCT05525858
recruitingphase_2

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

NCT06563999
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07704658Phase 4

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

Recruiting
NCT04589845Phase 2

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Active Not Recruiting
NCT04302025Phase 2

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Recruiting
NCT05525858

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

Recruiting
NCT06563999Phase 2

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Recruiting
NCT04222972Phase 3

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Terminated
NCT07418879Not Applicable

A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC

Not Yet Recruiting
NCT07010393Phase 4

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

Not Yet Recruiting
NCT04632992Phase 2

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed
NCT06482086Phase 2

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Recruiting
NCT04760288Phase 3

A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

Withdrawn
NCT04591431Phase 2

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12